Additionally, in silico differential analysis of PROM1, SOX2, and NANOG transcript levels was performed on clinical samples from GBM and low-grade glioma (LGG) and compared to healthy tissues as described in the Methods section. This evidence concerns the gene NANOG and glioblastoma.